Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (1634)	1/19/2000 9:52:00 AM
From: blackmerlin	Read Replies (1) \| Respond to of 1722

Bio-Technology General Wins Patent Suit Against Genentech Genentech Patent Ruled Invalid ISELIN, N.J.--(BUSINESS WIRE)--Jan. 19, 2000-- Bio-Technology General Corp. (NASDAQ: BTGC - news), a New Jersey biopharmaceutical company, today announced that in a lawsuit filed by BTG against Genentech, Inc., (NYSE: DNA - news), a New York court found invalid a Genentech U.S. patent relating to a method for producing recombinant human growth hormone. The ruling paves the way for the U.S. commercialization of BTG's recombinant human growth hormone, Bio-Tropin(TM), which received U.S. FDA approval in 1995. The trial, which took place in Manhattan in the United States District Court for the Southern District of New York, was presided over by U.S. District Judge Thomas P. Griesa. ``We are thrilled with the court's decision that Genentech's Patent No. 4,601,980 is invalid,' stated Sim Fass, Chairman and CEO of BTG. ``As a result of this landmark victory for BTG, the preliminary injunction that prohibited the commercial introduction in the United States of our recombinant human growth hormone, Bio-Tropin(TM), has been vacated. We expect to be in position to announce plans for commercialization of the product later this quarter.' The U.S. pediatric market for recombinant human growth hormones is approximately $325 million. Sales of Genentech's human growth hormone products amounted to approximately $214 million in 1998. Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. The Company's products are marketed in over thirty countries worldwide. Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are ``forward-looking statements' as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission. Contact: Wolfe Axelrod Weinberger Associates Don Weinberger 212/370-4500 or Bio-Technology General Corp. Leah Berkovits 732/632-8800